Evidence map›Paper›PMID 31048097›Full record

ArticleNeoplasia (New York, N.Y.)2019

Gene Expression Profiling Reveals Distinct Molecular Subtypes of Esophageal Squamous Cell Carcinoma in Asian Populations.

Fengling Wang, Zhongyi Yan, Jiajia Lv, Junfang Xin, Yifang Dang, Xiaoxiao Sun, Yang An, Yijun Qi, Qiying Jiang, Wan Zhu and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neoplasia (New York, N.Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. The consensus molecular subtypes of esophageal squamous cell carcinoma.Signal transduction and targeted therapy · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Neoadjuvant Chemoradiotherapy Upregulates the Immunogenicity of Cold to Hot Tumors in Esophageal Cancer Patients.Annals of surgery open : perspectives of surgical history, education, and clinical approaches · 2024
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Fengling WangDepartment of Preventive Medicine, Institute of Biomedical Informatics, Joint National Laboratory for Antibody Drug Engineering, Cell Signal Transduction Laboratory, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China.
Zhongyi YanDepartment of Preventive Medicine, Institute of Biomedical Informatics, Joint National Laboratory for Antibody Drug Engineering, Cell Signal Transduction Laboratory, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China.
Jiajia LvDepartment of Preventive Medicine, Institute of Biomedical Informatics, Joint National Laboratory for Antibody Drug Engineering, Cell Signal Transduction Laboratory, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China.
Junfang XinDepartment of Preventive Medicine, Institute of Biomedical Informatics, Joint National Laboratory for Antibody Drug Engineering, Cell Signal Transduction Laboratory, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China.
Yifang DangDepartment of Preventive Medicine, Institute of Biomedical Informatics, Joint National Laboratory for Antibody Drug Engineering, Cell Signal Transduction Laboratory, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China.
Xiaoxiao SunDepartment of Preventive Medicine, Institute of Biomedical Informatics, Joint National Laboratory for Antibody Drug Engineering, Cell Signal Transduction Laboratory, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China.
Yang AnDepartment of Preventive Medicine, Institute of Biomedical Informatics, Joint National Laboratory for Antibody Drug Engineering, Cell Signal Transduction Laboratory, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China.
Yijun QiHenan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang 471003, China.
Qiying JiangDepartment of Preventive Medicine, Institute of Biomedical Informatics, Joint National Laboratory for Antibody Drug Engineering, Cell Signal Transduction Laboratory, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China.
Wan ZhuDepartment of Anesthesia, Stanford University, 300 Pasteur Drive, Stanford, CA 94305, USA.
Yongqiang LiDepartment of Preventive Medicine, Institute of Biomedical Informatics, Joint National Laboratory for Antibody Drug Engineering, Cell Signal Transduction Laboratory, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China.
Ao LiSchool of Information Science and Technology, Centers for Biomedical Engineering, University of Science and Technology of China, Hefei 230027, China.
Xiangqian GuoDepartment of Preventive Medicine, Institute of Biomedical Informatics, Joint National Laboratory for Antibody Drug Engineering, Cell Signal Transduction Laboratory, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China. Electronic address: xqguo@henu.edu.cn.
Henan University · CNHenan University of Science and Technology · CNStanford University · USUniversity of Science and Technology of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Esophageal squamous cell carcinoma (ESCC) is one of the most common cancers worldwide, particularly in Asian populations, and responds poorly to conventional therapy. Subclassification of ESCCs by molecular analysis is a powerful strategy in extending conventional clinicopathologic classification, improving prognosis and therapy. Here we identified two ESCC molecular subtypes in Chinese population using gene expression profiling data and further validated the molecular subtypes in two other independent Asian populations (Japanese and Vietnamese). Subtype I ESCCs were enriched in pathways including immune response, while genes overexpressed in subtype II ESCCs were mainly involved in ectoderm development, glycolysis process, and cell proliferation. Specifically, we identified potential ESCC subtype-specific diagnostic markers (FOXA1 and EYA2 for subtype I, LAMC2 and KRT14 for subtype II) and further validated them in a fourth Asian cohort. In addition, we propose a few subtype-specific therapeutic targets for ESCC, which may guide future ESCC clinical treatment when further validated.

Indexed as

PrognosisAdultAgedAged, 80 and overAsian PeopleBiomarkers, TumorEsophageal Squamous Cell CarcinomaFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateMaleMicroarray AnalysisMiddle AgedNeoplasm ProteinsBiomarkers, TumorNeoplasm Proteins

Identifiers

PMID31048097
PMCPMC6495472
OpenAlexW2943342993

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.